

Retention samples

Document valid from: **10.04.2024**

Document number: **I-SMI.TI.03e** **Version 6.0**

Classification: **Public**

Replaced document: **I-SMI.TI.03_05** dated: 04.07.2023

Root SMI documents: --

Referenced QMI documents: --

Approval

	Date:	Signature:
Author:	<u>22.03.2024</u>	<u>Christian Eggel</u>
Technical verification:	<u>22.03.2024</u>	<u>Federico Cimini</u>
Formal verification (Release VS-QMI):	<u>10.04.2024</u>	<u>Michelle Scheidegger</u>

Index

1.	Purpose and scope	3
2.	Basics	3
3.	Definitions and abbreviations	3
4.	Interpretation.....	3
4.1	Standard situation	3
4.1.1	Conditions	3
4.2	Exceptional cases	4
4.2.1	Criteria	4
4.2.2	Possible alternatives to replace retention samples	4

4.2.3	Conditions.....	5
4.3	Medicinal products with safety features.....	5
4.4	Market release in cooperation with a pre-wholesaler.....	5
5.	Changes to the previous version.....	6
6.	Annexes.....	6

1. Purpose and scope

Article 12 paragraph 1 letter b of the Medicinal Products Licensing Ordinance (MPLO) requires that for each batch of ready to use medicinal product (the finished product), which is to be released for the (Swiss) market, a retention sample must be available.

In its definition of retention samples (see Chapter 3), Annex 19 of the Guide to GMP stipulates that “there may be exceptional circumstances where this requirement can be met without retention of duplicate samples e.g. where small amounts of a batch are packaged for different markets or in the production of very expensive medicinal products”.

This technical interpretation defines the circumstances where the requirement of keeping retention samples for finished products may be fulfilled with other means and describes such other means. In addition, it intends to clarify the requirements for retention samples in the case of medicinal products bearing safety features.

This Technical interpretation does apply to the requirements according to Article 12 MPLO for the Marketing Authorisation Holder only.

2. Basics

- Article 12 paragraph 1 letters a and b Medicinal Products Licensing Ordinance (MPLO; SR 812.212.1)

3. Definitions and abbreviations

MAH: Marketing Authorization Holder

Reference sample: A sample of a batch of starting material, packaging material, bulk product, semi-finished product or finished product which is stored for the purpose of being **analysed** should the need arise during the shelf life of the batch concerned. Where stability permits, reference samples from critical intermediate stages (e.g. those requiring analytical testing and release) or intermediates that are transported outside of the manufacturer’s control should be kept.

Retention sample: A sample of a fully packaged unit from a batch of finished product. It is stored for **identification** purposes. For example, presentation, packaging, labelling, patient information leaflet, batch number, expiry date should the need arise during the shelf life of the batch concerned.

Finished Product Product in its final pack which is ready to be released to the market (see also definition according to Article 2 letter c MPLO).

4. Interpretation

4.1 Standard situation

4.1.1 Conditions

Retaining retention samples of finished products in normal circumstances (majority of cases) should be done under the following conditions:

Duration of storage: at least one year after the expiry date of the batch.

Size of samples: at least one sample from each individual batch of finished product.

Storage conditions: no special requirements related to temperature, humidity, light (since they are not kept for analytical purposes). However, the readability of packaging materials should be ensured during the whole storage duration. It must also be considered that temperature and humidity might influence the adhesive characteristics of labels.

If stored in accordance with the Marketing Authorisation, retention samples may be interchangeable with reference samples. If such interchangeable sample has been used for analytical purposes, empty primary and secondary packaging material together with leaflet for patients should not be discarded but kept like any other retention sample until the end of the period of storage.

Place of storage: preferably at the site where the responsible person of the MAH releasing the batch for the Swiss market is located. Retention samples may be kept at a contract acceptor, if available for the MAH within a few hours (i.e. during any inspection by a competent authority).

4.2 Exceptional cases

In some exceptional cases other means than retention samples of the finished product can be accepted. Any proposed exception to this should be justified to, and agreed with the relevant competent inspectorate.

The responsible person of the MAH is responsible that the criteria and requirements for exceptional cases, the possible alternatives to replace retention samples and the conditions as listed below, are fulfilled.

4.2.1 Criteria

Exceptions may be made in individual cases. Following criteria may be used, alone or in combination (e.g. A with B), in order to justify exceptional cases:

- A. Packaging batch size smaller than 30 units (guidance value).
- B. Product retail price exceeding CHF 600.-.
- C. Short shelf life (less than 12 months).
- D. Large size of one packaged unit (e.g. some medicated feeds or medicated pre-mixes, multiple-units bags of solutions for infusion).

4.2.2 Possible alternatives to replace retention samples

The following alternatives to a retention sample of a finished product may be accepted if one or more criteria for exceptional cases is fulfilled:

- A. It is acceptable that only batch specific primary and secondary packaging materials are kept as retention samples. This material must include all variable data. This means that (the labelling of) the primary packaging material and the folding box (secondary packaging material), the patients leaflet and the dosing aids are available for a full visual check.
- B. Alternatively, colour photographs or photocopies of batch specific primary and secondary packaging material, i.e. labelling of primary packaging material, folding box (secondary packaging material) and patients leaflet can be accepted. Thus, photographs should be easily readable and should cover all relevant aspects for a full visual check (i.e. including lot number and version of the secondary packaging material and any markings or texts directly applied on primary packaging, e.g. ampoules).

The retention of colour photographs or photocopies must allow the identification of a hologram, of specially coloured glue, information given in braille, information on dosing aids or of

other special secondary packaging markings which may be used in order to facilitate the distinction between an original and a counterfeit product.

The whole process, including unpacking and repacking of the samples, must be described in an SOP. The company does need an establishment license for this activity (this does not have to be a manufacturing license).

4.2.3 Conditions

Duration of storage: at least one year after the expiry date of the batch.

Size of packaging material samples: at least one sample of packaging material from each batch of finished product.

Storage conditions of packaging material samples: no special requirement related to temperature, humidity, light. However the readability of materials replacing retention samples should be ensured during the whole storage duration.

Place of storage: preferably at the site where the responsible person of the MAH releasing the batch for the Swiss market is located. It may be kept at a contract acceptor, if available for the MAH within a few hours (i.e. during any inspection).

Traceability of packaging material samples or photographs/photocopies of packaging batch records: the traceability should be ensured and documented, e.g. through batch records or a statement from the responsible person of the Swiss MAH that the packaging materials or the photographs of the packaging materials are identical with those of the released batch of medicinal product.

4.3 Medicinal products with safety features

For medicinal products bearing safety features three options are possible:

- A. The medicinal product falls under the criteria for exceptional cases: Retention samples can be replaced by the alternatives expressed under section 4.2.2 (conditions according to section 4.2.3 apply). If option 4.2.2.A is selected, it should be complemented by pictures of the package unit showing the presence of the safety features.
- B. The medicinal product does not match any criteria for exceptional cases under section 4.2.1:
 - B.1 Unopened samples are kept together with opened samples used for control purposes.
 - B.2 Samples opened for control purposes are kept as unique reference samples. In that case, evidence must be kept of the original package before opening (colour photographs), to ensure that the safety features were present and integer.

4.4 Market release in cooperation with a pre-wholesaler

If one of the alternatives described above in sections 4.2.2 and 4.3 is applied and distribution is in collaboration with a pre-wholesaler, it should be ensured that pictures of the secondary packaging e.g. taken by the pre-wholesaler upon receipt of goods at the storage location are available on site at the MAH. This information together with copies of the manufacturer's packaging batch documentation (covering primary packaging and patient leaflet), must be reviewed by the MAH at the time of market release. All documentation for primary/secondary packaging and patient leaflet must be available on short notice at the MAH.

5. Changes to the previous version

- Formal adaptations
- Chapter 4.3: Medicinal products with safety features as a separate chapter
- Chapter 4.4: Market release in cooperation with pre-wholesaler as a separate chapter

6. Annexes

- None